Cargando…
GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials
BACKGROUND: The main objective of phase I cancer clinical trials is to identify the maximum tolerated dose, usually defined as the highest dose associated with an acceptable level of severe toxicity during the first cycle of treatment. Several dose-escalation designs based on mathematical modeling o...
Autores principales: | Dinart, D., Fraisse, J., Tosi, D., Mauguen, A., Touraine, C., Gourgou, S., Le Deley, M. C., Bellera, C., Mollevi, C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469913/ https://www.ncbi.nlm.nih.gov/pubmed/32580715 http://dx.doi.org/10.1186/s12911-020-01149-3 |
Ejemplares similares
-
Optimal biological dose: a systematic review in cancer phase I clinical trials
por: Fraisse, J., et al.
Publicado: (2021) -
Software-based analysis of bacteriophage genomes, physical ends, and packaging strategies
por: Merrill, Bryan D., et al.
Publicado: (2016) -
TCC: an R package for comparing tag count data with robust normalization strategies
por: Sun, Jianqiang, et al.
Publicado: (2013) -
When a joint model should be preferred over a linear mixed model for analysis of longitudinal health-related quality of life data in cancer clinical trials
por: Touraine, Célia, et al.
Publicado: (2023) -
DrugTax: package for drug taxonomy identification and explainable feature extraction
por: Preto, A. J., et al.
Publicado: (2022)